Remove

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10596571	
Filing Date			
First Named Inventor	Nicho	olas David Wingham Rowan	
Art Unit			
Examiner Name			
Attorney Docket Numb	er	GPC0102PUSA	

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Patentee or Applicant of cited Document		Releva		ines where es or Relev	
	1	6330551	B1	2001-12	9-11	cybersettle.com, Inc					
	2	5495412	A	1996-02	-27	ICAN Systems Inc.					
	3	5895450	A	1999-04	-20	Sioo					
	4	5794207	A	1998-08	l-11	Walker Asset Limited Partne					
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	of cited Document		Releva		ines where es or Relev		
	1	20040139032	A1	2004-07	-15	Rowan					
If you wish to add additional U.S. Published Application citation information please click the Add button. Add											
FOREIGN PATENT DOCUMENTS Remove											
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or V	vhere Rele	or Relevant	TS

U.S.PATENTS

INFORMATION DIGGI COURT			Filing Date								
INFORMATION DISCLOSURE		First Named Inventor Nicho				olas David Wingham Rowan					
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			Art Unit								
			,	Examiner Name							
					Attorn	ey Doc	ket Numb	er	GPC0102PUSA		
		1									
	If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
				NON-	PATE	IT LITE	RATURE	DOC	UMENTS	Remove	
	Examiner Initials*	Cite No	Include name of the au (book, magazine, journ publisher, city and/or c	nal, serial	l, symp	osium,	catalog, et				m Ts
		1									

Application Number

10596571

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINED SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See for Code of USPTO Platent Documents at year, LISPTO,000 or MPEP 901.04. * Enter office and assued the document, by the to-elect code (VIPO Standard ST3,). * Explanese parted convenient, the notication of the parent for seign or the Engerent mate procedure the senior number of the patent country. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST,168 possible. * Applicant is to place a check mark here fittingle language arrelation is statistical.

| Application Number | 10596571 | Filing Date | The Number | 10596571 | Filing Date | The Number | 10596571 | Filing Date | The Number | Nucleotian David Wingham Rowan | Art Unit | Examiner Name | Carpon Date Number | GPC0102PUSA | Application Number | GPC0102PUSA | Application Number | 10596571 | The Number | Number | Number | Number | Number | Number | GPC0102PUSA | Application Number | 10596571 | The Number | N

CERTIFICATION STATEMENT

Diagra can	37 (FR 1	97	and 1	QR to	make the	annronniate	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sec 3.7 CFR 1.97(eVI.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inequiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/John E. Nemazı/	Date (YYYY-MM-DD)	2006-08-18
Name/Print	John Nemazi	Registration Number	30876

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2311-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to a patient application or patient. If you do not furnish the requested the process another examine your submission, which may visually intermediate or of redesting to a submission or the basic log process another examine; your submission, which may visually intermediate or of redesting to a submission or the submission or the submission of the submission or the submission of the submission of the submission or the submission of the submission or the submission of the submission or the submission or the submission of the submission or the submission or the submission or the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.